The use of PDE4 inhibitors as a therapeutic approach for inflammatory disorders has been validated by treating conditions such as neuroinflammation, RA, lupus, inflammatory bowel disease, asthma, dermatitis, psoriasis, atopic conditions, and chronic obstructive pulmonary disease
Other Level C studies, while not necessarily measuring barrier function directly, observed systemic inflammation and pathological improvements against a backdrop of microbiota structural change/metabolic profile remodeling, including YBTC, WJT, FPTF, ELP, DBZP, TFP, DSD, CBN, Atractylodes koreana, CTSs, and DZGP (Guo et al., 2019
Aoi, W., Ogaya, Y., Takami, M., Konishi, T., Sauchi, Y., Park, E
Telehealth-only: Yes online evaluation, physician-supervised protocols Menu: BPC-157 (Wolverine), MOTS-c, GHK-Cu, CJC-1295/Ipamorelin, Tesamorelin, Glutathione, NAD+, Retatrutide & more Insurance: Not accepted
Research has shown that glutathione deficiency is related to premature ovarian aging and even ovarian cancer